EcoDrugPlus

Hyperpolarization Activated Cyclic Nucleotide Gated Potassium Channel 4

Ensembl ID : ENSNFUG00015019726
Gene Symbol: HCN4
3 Cross references
212 Possible Orthologues:

Hyperpolarization Activated Cyclic Nucleotide Gated Potassium Channel 4

Ensembl ID : ENSNFUG00015008444
Gene Symbol: HCN4
3 Cross references
221 Possible Orthologues:

Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 Homolog

Ensembl ID : ENSNFUG00015019428
Gene Symbol: LOC107379220
3 Cross references
211 Possible Orthologues:

Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Beta

Ensembl ID : ENSNFUG00015015755
Gene Symbol: IKBKB
3 Cross references
199 Possible Orthologues:

Inosine Monophosphate Dehydrogenase 2

Ensembl ID : ENSNFUG00015011486
Gene Symbol: IMPDH2
3 Cross references
200 Possible Orthologues:

Inosine-5'-Monophosphate Dehydrogenase 1b

Ensembl ID : ENSNFUG00015004128
Gene Symbol: LOC107385731
3 Cross references
257 Possible Orthologues:

Inositol Polyphosphate-5-Phosphatase D

Ensembl ID : ENSNFUG00015005120
Gene Symbol: INPP5D
1 Cross references
215 Possible Orthologues:

Insulin Receptor A

Ensembl ID : ENSNFUG00015024774
Gene Symbol: INSRA
1 Cross references
213 Possible Orthologues:

Insulin Receptor-Like

Ensembl ID : ENSNFUG00015025450
Gene Symbol: LOC107392644
3 Cross references
212 Possible Orthologues:

Insulin-Like Growth Factor 1 Receptor

Ensembl ID : ENSNFUG00015008221
Gene Symbol: LOC107382005
3 Cross references
203 Possible Orthologues:

Insulin-Like Growth Factor 1a Receptor

Ensembl ID : ENSNFUG00015011508
Gene Symbol: IGF1RA
1 Cross references
204 Possible Orthologues:

Integrin Alpha-5-Like

Ensembl ID : ENSNFUG00015013119
Gene Symbol: LOC107385841
3 Cross references
197 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).